RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF PIVAGABINE IN NEURASTHENIA

One hundred and eighteen patients with neurasthenia, as defined by ICD 10(International Classification of Diseases), participated in a rando mised, double-blind, placebo-controlled trial of pivagabine (4-[(2,2-d imethyl-1-oxopropyl) amino] butanoic acid, CAS 69542-93-4, Tonerg(R)). Pivagabine administered orally for four weeks. At the end of the tria l, active medication was significantly superior to placebo on the Clin ical Global Impression (CGI) improvement of illness scale. In addition , pivagabine treatment reduced the physical and mental fatigability of patients, and increased their sense of well-bring.